Why Roche Holdings Stock Withered on Wednesday
For the second trading session in less than a week, Roche Holding (OTC: RHHBY) stock really took it on the chin Wednesday. Dispiriting news about its investigational obesity drug was the culprit; disseminating this, investors sold out of the pharmaceutical veteran. At the end of the day's action, Roche had lost almost 6% of its value.
In a meeting of the European Association for the Study of Diabetes that day, Roche presented the results of an early-stage clinical trial of its CT-996 pill.
This is the Switzerland-based company's bid to compete in the very high-potential weight-loss drug market. At the moment, this is dominated by fellow European pharmaceutical company Novo Nordisk's Wegovy. A more recent arrival, muscular U.S. peer Eli Lilly, is also competing in the segment with its Zepbound.
Source Fool.com
Roche Holding AG ADR Aktie
Mit 4 Buy-Einschätzungen und 3 Sell-Einschätzungen hat die Community keine klare Richtung bezüglich der Roche Holding AG ADR Aktie.
Ein positives Kurspotenzial für Roche Holding AG ADR ist gegeben, mit einem Kursziel von 38 € über dem aktuellen Kurs von 35.91 €.
